LOS ANGELES, June 20, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Biogen Inc. ("Biogen" or "the Company") (NASDAQ: BIIB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 3, 2022 and February 13, 2024, inclusive (the "Class Period"), are ...

NEW YORK , June 20, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Biogen Inc. (NASDAQ: BIIB). Shareholders who purchased shares of BIIB during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/biogen-loss-submission-form/?id=86310&from=4 CLASS PERIOD: February 3, 2022 to February 1 ...

The Alzheimer's treatment landscape presents a compelling opportunity for investors in healthcare and biotech. Alzheimer's disease is a progressive and debilitating neurodegenerative disorder that poses a significant and growing threat to global health and economic well-being. With an estimated 6.7 million Americans currently living with Alzheimer's and projected costs exceeding $2 trillion over the next decade, the urgency for effective treatments is undeniable. This unmet medical need has created an arena ...

NEW YORK, June 18, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Biogen Inc. (NASDAQ: BIIB). Shareholders who purchased shares of BIIB during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/biogen-loss-submission-form/?id=85786&from=3 CLASS PERIOD: February 3, 2022 to Februar ...

RADNOR, Pa., June 17, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc. ("Biogen") (NASDAQ: BIIB). The action charges Biogen with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Biogen's mate ...

NEW YORK, June 17, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Biogen Inc. (NASDAQ: BIIB). Shareholders who purchased shares of BIIB during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/biogen-loss-submission-form/?id=85496&from=4 CLASS PERIOD: February 3, 2022 to February 13 ...

The healthcare sector will be one area of secular growth over the next decade. Several demand drivers will benefit the best healthcare stocks to buy across the entire value chain. First, let’s highlight the major healthcare tailwinds starting with an aging population. The baby boomer generation (20% of the U.S. population) is transitioning into older age. This shift will create a surging demand for healthcare services and products such as insurance, pharmaceuticals, medical devices and hospitals. Indeed, es ...

NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the District of Colorado on behalf of those who acquired Biogen, Inc (“Biogen” or the “Company”) (NASDAQ: BIIB) securities during the period of February 3, 2022 through February 13, 2024, inclusive (“the Class Period”). Investors have until July 22, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit. [Click here t ...

NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq: BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/biogen-inc-investigation. Why is Biogen being Sued? On May 22, 2024, Biogen was sued for violations of the federal securities laws. The complaint alleges that between February 3, 2022 and Fe ...

会议主要讨论的核心内容 - Biogen公司在过去几年经历了重大转型 [4][5][6][7] - 公司现已进入稳定期并正在向增长转型 [5][6][7] - 公司正在优化资本配置以实现长期增长 [6][7] - 公司正在推出新产品并拓展管线 [7] LEQEMBI上市情况 - LEQEMBI上市10个月来经历了两个阶段 [11][12][13][14][15][16][17] - 3月份开始出现加速增长 [16][17][18][19][20] - 主要原因包括更多医生开始开具处方、医疗机构扩大患者数量 [16][17][18][19][20] - 公司正在扩大销售团队以支持进一步增长 [37][38][39][40] - 公司关注医生开具处方数量和医疗机构订单数量等指标 [25][26][27][28][29][30][31][32][33][34][35] - 预计竞争对手进入市场将有利于整体市场发展 [21][22][23] SKYCLARYS上市情况 - SKYCLARYS上市表现良好 [54][55][56][57][58][59] - 公司正在采取多种策略寻找更多患者 [56][57][58][59] - 预计儿童适应症获批将带来约500名新患者 [67][68] - 欧洲市场也有较大发展空间 [69][70][71] ZURZUVAE上市情况 - 与Sage公司合作共同推广 [73][74][75][76][77][78][79][80] - 出现意外情况,产品主要由妇产科医生而非精神科医生开具 [74][75][76][77] - 公司正在加强对医生的教育培训 [79][80] 公司整体情况 - 公司正在优化资本配置以提升利润率 [83][84][85][86][87][88] - 公司仍有业务拓展需求,未来将继续进行适当的并购 [85][86][87]